Feedback
Settings

Settings

Goto Application

1. WO2022008469 - COMBINATION OF A METHIONINE AMINOPEPTIDASE 2 INHIBITOR AND VEGFR/VEGF INHIBITOR

Submit observation
PermaLink
Publication Number WO/2022/008469
Publication Date 13.01.2022
International Application No. PCT/EP2021/068564
International Filing Date 06.07.2021
IPC
A61K 31/404 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
40having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
403condensed with carbocyclic rings, e.g. carbazole
404Indoles, e.g. pindolol
A61K 31/416 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
41having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
4151,2-Diazoles
416condensed with carbocyclic ring systems, e.g. indazole
A61K 31/44 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
44Non-condensed pyridines; Hydrogenated derivatives thereof
A61K 31/443 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
44Non-condensed pyridines; Hydrogenated derivatives thereof
4427containing further heterocyclic ring systems
443containing a five-membered ring with oxygen as a ring hetero atom
A61K 31/444 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
44Non-condensed pyridines; Hydrogenated derivatives thereof
4427containing further heterocyclic ring systems
444containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
A61K 31/47 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
47Quinolines; Isoquinolines
Applicants
  • MERCK PATENT GMBH [DE]/[DE]
Inventors
  • FRIESE-HAMIM, Manja
  • ROHDICH, Felix
  • GIMMI, Claude
  • SCHULTES, Christoph
  • BOGATYROVA, Olga
Priority Data
20184962.709.07.2020EP
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) COMBINATION OF A METHIONINE AMINOPEPTIDASE 2 INHIBITOR AND VEGFR/VEGF INHIBITOR
(FR) COMBINAISON D'UN INHIBITEUR DE LA MÉTHIONINE AMINOPEPTIDASE 2 ET D'UN INHIBITEUR DE VEGFR/VEGF
Abstract
(EN) The invention relates to combinations of (S)-3-Hydroxy-1-(1H-indol-5-yl)-2-oxo- pyrrolidine-3-carboxylic acid 3,5-difluoro-benzylamide and a VEGFR/VEGF inhibitor, or their physiologically acceptable salts, as well as to the use of such combinations for the prophylaxis or treatment of cancer.
(FR) L'invention concerne des combinaisons de (S)-3-hydroxy-1-(1H-indol-5-yl)-2-oxo-pyrrolidine-3-carboxylique et un 3,5-difluoro-benzylamide d'acide-2-oxo-pyrrolidine-3-carboxylique et d'un inhibiteur VEGFR/VEGF, ou leurs sels physiologiquement acceptables, ainsi que l'utilisation de telles combinaisons pour la prophylaxie ou le traitement du cancer.
Latest bibliographic data on file with the International Bureau
# -